SCHEMBL3483931

SCHEMBL3483931

COC(=O)C(C)(C)CCCOc1cccc(-c2ccc(C)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.53
PPARA Q07869 3/20 0.45
FFAR1 O14842 2/20 0.45
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
SLC13A5 Q86YT5 1/20 0.43
POLB P06746 1/20 0.43
CYP1A2 P05177 2/20 0.42
MAPT P10636 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
TTR P02766 1/20 0.41
CYP2C8 P10632 1/20 0.41
CHRM1 P11229 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
ADRA1A P35348 1/20 0.41
PPARG P37231 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4035381 0.88 PPARA (0.60) FFAR4PPARAFFAR1HDAC1HDAC2
SCHEMBL3485000 0.87 PPARA (0.58) FFAR4PPARAHDAC1HDAC2CYP1A2
SCHEMBL3484666 0.87 SLC13A5 (0.45) FFAR4PPARAFFAR1HDAC1HDAC2
SCHEMBL3485054 0.86 FFAR4 (0.47) FFAR4FFAR1RXRARXRBPOLB
SCHEMBL10683854 0.83 PPARA (0.62) PPARACYP1A2SMN1; SMN2TTRCYP2C8
SCHEMBL28137761 0.79 PPARA (0.68) FFAR4PPARAFFAR1HDAC1HDAC2
SCHEMBL3484594 0.77 LMNA (0.48) PPARACYP1A2SMN1; SMN2TTRCYP2C8
SCHEMBL20231195 0.76 FFAR4 (0.54) FFAR4FFAR1RXRARXRBPOLB
SCHEMBL11707662 0.76 PPARA (0.52) PPARAPOLBMAPTDRD2DRD4
SCHEMBL4037965 0.76 CYP2C9 (0.52) FFAR4FFAR1HDAC1HDAC2RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES IPO5, PPIP5K2, IPO4 FFAR4 3179/4885PPARA 1045/4885FFAR1 4430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.